Processa Pharmaceuticals
Yahoo Finance • 26 days ago
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story
Yahoo Finance • 2 months ago
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading
(RTTNews) - Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from Novembe... Full story
Yahoo Finance • 2 months ago
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases,... Full story
Yahoo Finance • 5 months ago
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it... Full story
Yahoo Finance • 6 months ago
Processa Pharmaceuticals to reconvene annual meeting after achieving quorum
Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), a micro-cap pharmaceutical company with a market capitalization of $5.61 million, will reconvene its Annual Shareholder Meeting on Thursday in Hanover, Maryland, after obtaining a sufficient n... Full story
Yahoo Finance • 7 months ago
Processa Pharmaceuticals adjourns annual meeting due to lack of quorum
Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), a micro-cap pharmaceutical company with a market value of $5.39 million, adjourned its annual shareholder meeting on Monday in Hanover, Maryland, after failing to reach a quorum. The company a... Full story
Yahoo Finance • 7 months ago
Processa Pharmaceuticals price target lowered to $2 at H.C. Wainwright
Investing.com - H.C. Wainwright lowered its price target on Processa Pharmaceuticals (NASDAQ:PCSA) stock to $2.00 from $6.00 on Monday, while maintaining a Buy rating on the shares. The stock, currently trading at $0.20, has declined ove... Full story
Yahoo Finance • 7 months ago
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the Company), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced the pricing of a publ... Full story
Yahoo Finance • 7 months ago
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leade... Full story
Yahoo Finance • 8 months ago
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today ann... Full story
Yahoo Finance • 11 months ago
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved eff... Full story
Yahoo Finance • 11 months ago
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with... Full story
Yahoo Finance • 12 months ago
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with... Full story
Yahoo Finance • 2 years ago
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to im... Full story
Yahoo Finance • 2 years ago
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs t... Full story
Yahoo Finance • 2 years ago
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson served on our Boa... Full story
Yahoo Finance • 2 years ago
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to im... Full story
Yahoo Finance • 2 years ago
Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq... Full story
Yahoo Finance • 2 years ago
Processa Pharmaceuticals to Present at the ThinkEquity Conference
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to im... Full story
Yahoo Finance • 2 years ago
Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
HANOVER, MD, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to i... Full story
